MedTrace Logo

Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer

NCT03096093 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-01-20

No results posted yet for this study

Summary

This study evaluates four different doses of ACIT-1 for safety and for the ability to raise effective anti-cancer immune responses in patients with pancreatic and other cancers. Approximately half of the patients will have pancreatic cancer and the other half will have other cancers.

Conditions

Interventions

BIOLOGICAL

ACIT-1

Cell suspension

Sponsors & Collaborators

  • Liverpool University Hospitals NHS Foundation Trust

    collaborator OTHER_GOV

  • The Clatterbridge Cancer Centre NHS Foundation Trust

    collaborator OTHER

  • University of Liverpool

    collaborator OTHER

  • Cancer Research UK

    collaborator OTHER

  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV

  • Cancer Vaccines Charitable Trust

    collaborator UNKNOWN

  • Cancer Vaccines Limited

    lead INDUSTRY

Principal Investigators

  • Daniel H Palmer, MBChB PhD · Clatterbridge Cancer Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-25
Primary Completion
2026-12-31
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03096093 on ClinicalTrials.gov